Samsung Bioepis acquired domestic approval for Brenzys™
Samsung Bioepis and MSD Korea announced the Samsung Bioepis’s first biosimilar, Brenzys™, has been approved by the Ministry of Food and Drug Safety(MFDS) on the 7th.
The MFDS approved Brenzys™ to be used for rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis(ankylosing spondyliti...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
